Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

11.1%

6 terminated/withdrawn out of 54 trials

Success Rate

86.7%

+0.1% vs industry average

Late-Stage Pipeline

15%

8 trials in Phase 3/4

Results Transparency

15%

6 of 39 completed trials have results

Key Signals

2 recruiting6 with results

Enrollment Performance

Analytics

Phase 1

23(45.1%)

Phase 2

15(29.4%)

Phase 3

7(13.7%)

N/A

5(9.8%)

Phase 4

1(2.0%)

51Total

Phase 1(23)

Phase 2(15)

Phase 3(7)

N/A(5)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (54)

Showing 20 of 54 trials

NCT05572333Phase 2Completed

Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD

Role: collaborator

NCT05389319Phase 1Active Not Recruiting

A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults

Role: collaborator

NCT07433335Phase 1Recruiting

A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis

Role: collaborator

NCT05516316Phase 1Completed

Clinical Trial Comparing the Pharmacological Effects of EP395 With Placebo in Healthy Adults

Role: collaborator

NCT04387409Phase 3Completed

Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic

Role: collaborator

NCT06168799Phase 2Completed

Ilofotase Alfa for Prevention of Renal Damage After Cardiac Surgery

Role: collaborator

NCT04971161Phase 2Completed

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)

Role: collaborator

NCT06677918Phase 1Completed

Clinical Trial Investigating the Effects of EP395 Following an Inhaled Endotoxin Challenge in Healthy Adults

Role: collaborator

NCT06489028Phase 3Active Not Recruiting

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)

Role: collaborator

NCT06211049Phase 3Completed

Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea

Role: collaborator

NCT06191042Phase 1Completed

A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

Role: collaborator

NCT05365672Phase 2Recruiting

Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation

Role: collaborator

NCT01798498Not ApplicableCompleted

Study for the Evaluation of the Efficacy and Safety of the Dermal Filler Princess® VOLUME in Nasolabial Folds

Role: collaborator

NCT03400059Not ApplicableCompleted

Study to Evaluate the Efficacy of Intranasal Kinetic Oscillation Stimulation in the Preventive Treatment of Chronic Migraine

Role: collaborator

NCT03532126Completed

A 52-week Clinical Investigation of Princess® VOLUME PLUS Lidocaine in Subjects With Midface Volume Deficit

Role: collaborator

NCT01744418Not ApplicableCompleted

Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRD

Role: collaborator

NCT01872208Not ApplicableCompleted

Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With PAD

Role: collaborator

NCT04379271Phase 2Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)

Role: collaborator

NCT04429919Phase 2Completed

AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain

Role: collaborator

NCT04263649Completed

Prospective Observational Study of the Power PICC Family of Devices and Accessories

Role: collaborator